今年年初，Deepseek横空出世，在全球人工智能领域掀起惊涛骇浪，亦为量化投资领域注入了新的活力，叠加年内中小盘风格占优的市场环境下，量化投 资更是火出圈。另外，在刚刚过去的11月，A股市场整体呈现调整态势，交投活跃度降低、投资者风险偏好明显收敛下，以股票策略为主的百亿私募旗下 仍有不少产品逆势创下历史新高，且量化产品占比超过八成！ 为了能更清晰了解量化私募基金的业绩，经笔者统计，在私募排排网上有业绩展示的量化产品共有1833只，今年来收益均值达26.98%，今年来超额（几 何）收益达11.41%；其中量化多头策略产品多达833只，今年来收益和超额（几何）收益分别为40.34%、17.25%，在私募二级策略中居前。 | 排序 | 私募二级策略 | 有业绩展示的量化产品 | 今年来收益均值 | 今年来超额收益均值 | | --- | --- | --- | --- | --- | | 1 | ■化务杀 | 833 | 40.34% | 17.25% | | 2 | 量化CTA | 379 | 16.32% | 13.76% | | 3 | 股票市场中性 | 200 | 9.37% | -4.93% | | 4 ...

私募排排网最新数据显示，截至2025年11月21日，蒙玺投资旗下今年以来有业绩展示且符合排名规则的产品共有10只，均由李骧管理，今年 来平均收益为***%。其中，有8只为量化多头产品，它们今年来的平均超额收益为***%。（ 点击查看收益 ） [应监管要求，私募产品不能公开展示业绩，文中涉及收益数据用***替代，合格投资者可扫码查看收益数据。] 本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 今年以来，在市场流动性改善以及友好的策略环境下，多家量化私募凭借着其投研、风控、策略优势，进入百亿私募阵营。蒙玺投资就是其中一 家新晋的百亿量化私募。 蒙玺投资成立于2016年，是国内量化行业先行者之一。 依托强大的数据挖掘、统计分析和软件开发能力， 公司构建了覆盖多市场、多品种、 全频段的量化资产管理平台 。公司自主研发的低延迟交易策略和系统，经长期实践检验，形成一定技术壁垒，业绩表现获得了市场广泛认可。 蒙玺投资的投研团队有60余人，具备世界顶级高校的物理、数学、金融等多元学科背景。另外，公司在数据方面资源储备充足，除常用的量 价、基本面数据外，每年额外有千万级别另类数据购买成本，构建来自全球200+的 ...

Core Viewpoint - The A-share market showed strong performance in August, with major indices rising significantly, yet the excess returns of stock strategy private equity products were disappointing, marking the worst monthly performance of the year [1][2]. Group 1: Market Performance - In August, the Shanghai Composite Index rose by 7.97%, the Shenzhen Component Index increased by 15.32%, and the ChiNext Index surged over 24% [1]. - Despite the strong market, the average excess return of 3,122 stock strategy private equity products was -1.97%, the worst monthly performance this year [1]. Group 2: Quantitative vs. Subjective Strategies - Quantitative private equity products experienced a notable decline, with an average excess return of -3.94% in August, while subjective private equity products had an average excess return of -1.00% [1]. - The significant decline in quantitative products is attributed to a reversal in style, particularly the outperformance of large-cap stocks over small-cap stocks, and severe sector differentiation due to rapid growth in financing scale [1][2]. Group 3: Consistent Performers - As of August 2025, only 95 stock strategy private equity products achieved positive excess returns for eight consecutive months, representing about 3% of the total [2]. - Among private equity firms with over 10 billion in assets, 46 products achieved positive excess returns for eight consecutive months, all of which were quantitative products, with an average excess return of 0.63% in August and 17.91% year-to-date [3]. Group 4: Top Performers by Asset Size - In the 20-100 billion category, 14 products achieved positive excess returns for eight consecutive months, with an average excess return of 1.83% in August and 22.48% year-to-date [7]. - The top three products in this category were "New Thinking Multi-Strategy 3", "Pansong Micro-Cap Index Enhanced 1", and "Giraffe 7", with year-to-date excess returns of ***% [11]. Group 5: Small and Emerging Firms - In the 5-20 billion category, 13 products achieved positive excess returns for eight consecutive months, with an average excess return of 5.34% in August and 57.58% year-to-date [13]. - The leading product in the 0-5 billion category was "Zijin Yunsong", achieving a year-to-date excess return of ***% [18].

Core Viewpoint - The article highlights the strong performance of quantitative long products from billion-level private equity firms in the A-share market since August, with average returns significantly increasing for various strategies [1]. Summary by Category Quantitative Stock Selection Products - As of August 22, 2025, there are 234 quantitative long products under billion-level private equity firms, with an average return of ***% this year [1]. - The top-performing products in the quantitative stock selection category have shown an average return close to ***% [1]. Top 10 Products in the "CSI 1000 Index Enhancement" Category - The article lists the top 10 products in the "CSI 1000 Index Enhancement" category, with the leading product being "Mengxi CSI 1000 Quantitative No. 5 A-Class" managed by Li Ji from Mengxi Investment [4]. - Other notable products include "Qianyan Liuhe No. 6 1000 Enhancement B-Class" and "Mingfa Quantitative Small Cap Enhancement No. 1 B-Class" [4]. Top 10 Products in the "CSI 300 Index Enhancement" Category - The leading product in the "CSI 300 Index Enhancement" category is "Jiu Zhang Huan Fang CSI 300 Quantitative Multi-Strategy No. 1," managed by Xu Jin from Ningbo Huan Fang Quantitative [7]. - Other top products include "Mingxuan Stable Growth No. 2" and "Zhengding CSI 300 Index Enhancement No. 1 B-Class" [7]. Top 10 Products in the "CSI 500 Index Enhancement" Category - The article provides a list of the top products in the "CSI 500 Index Enhancement" category, highlighting the competitive performance of various funds [10]. Top 10 Products in the "Other Index Enhancement" Category - The article also details the top products in the "Other Index Enhancement" category, showcasing the diversity of strategies employed by different private equity firms [14]. Notable Firms and Strategies - Mengxi Investment has established a strong reputation with its quantitative strategies, leveraging a team with significant academic backgrounds in quantitative finance [16]. - Ningbo Huan Fang Quantitative has also gained recognition for its high returns, particularly in the CSI 300 Index Enhancement category [19].